<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Summit Therapeutics&#x27; Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Summit Therapeutics&#x27; Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences</h2>
    <div class="badge">2025-09-08T12:28:07+00:00</div>
    <ul>
      <li>In September 2025, an additional analysis included longer-term follow-up of Western patients (median follow-up time of Western patients of 13.7 months).</li>
<li>4.4 months, respectively.</li>
<li>placebo plus chemotherapy was 6.8 months vs.</li>
<li>(NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer (WCLC).</li>
<li>The statistical analysis plan for the study required a p-value of 0.0448 to achieve statistical significance.</li>
<li>Median overall survival was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy.</li>
<li>Data showed a hazard ratio consistent with the primary analysis was observed with an improved nominal p-value (HR=0.78; nominal p=0.0332).</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Summit Therapeutics&amp;#x27; Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences\n• In September 2025, an additional analysis included longer-term follow-up of Western patients (median follow-up time of Western patients of 13.7 months).\n• 4.4 months, respectively.\n• placebo plus chemotherapy was 6.8 months vs.\n• (NASDAQ:SMMT), on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 World Conference on Lung Cancer (WCLC).\n• The statistical analysis plan for the study required a p-value of 0.0448 to achieve statistical significance.\n• Median overall survival was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy.\n• Data showed a hazard ratio consistent with the primary analysis was observed with an improved nominal p-value (HR=0.78; nominal p=0.0332)." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/summit-therapeutics-lung-cancer-drug-122807408.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>